Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological, Metabolic, and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UNC13B (Munc13-2) mechanism research, synaptic vesicle exocytosis, and insulin secretion pathway validation. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-length & Domain) | UNC13B Recombinant Protein / C2A-C2B Tandem Domain / MUN Domain HEK293 Expressed, Sequence Verified, >95% Purity, Endotoxin <1EU/µg |
View UNC13B Products |
| Gene Delivery | UNC13B Lentivirus Premade Particles Full-length ORF for stable cell lines (neuronal, beta-cell) |
View UNC13B Products |
| Benchmark Ab | Anti-UNC13B Benchmark Antibody (Clone N476/28) Recombinant positive control for Western/IP, Host: Rat |
View UNC13B Products |
| Validator | UNC13B siRNA Set (3 unique sequences) For knockdown verification in glucose-stimulated insulin secretion or exocytosis assays |
View UNC13B Products |
| Related Target A | STX1A (Syntaxin-1A) SNARE complex binding partner, critical for vesicle fusion assays |
View STX1A Products |
| Related Target B | VAMP2 (Vesicle-associated membrane protein 2) Synergistic synaptic vesicle marker |
View VAMP2 Products |
| Regulatory Complex | Munc18-1 (STXBP1) Essential cofactor for UNC13B-mediated priming |
View STXBP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-dependent Lipid Binding (C2 Domains) | High-purity C2A-C2B tandem construct with confirmed theoretical MW; suitable for liposome sedimentation assays |
| MUN Domain Conformational Integrity | HEK293 expression system ensures proper folding; Endotoxin controlled (<1EU/µg) for sensitive cell-based priming assays |
| SNARE Complex Assembly Kinetics | Matched Syntaxin-1A and SNAP-25 proteins available with same expression host for consistent interaction studies |
| Subfamily Counter Screening | UNC13A / UNC13C homolog proteins strictly verified by mass spec for off-target selectivity |
| Lack of Controls | Sequence-verified Benchmark Antibodies included |
| False Positives in Knockdown | Validated siRNA included for specificity checks |
Live UNC13B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Latest Metabolic Disease Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for UNC13B-targeted therapeutics is intensifying as its role in synaptic vesicle exocytosis and potential implications in neurodevelopmental disorders, metabolic disease (Type 2 Diabetes, congenital hyperinsulinism), and specific neuro-oncology pathways become clearer. Unlike receptor-based targets, UNC13B represents a vesicle priming machinery component—positioning it as a high-value target for small-molecule-mediated enhancement of insulin secretion or modulation of neurotransmitter release. Current R&D focuses on allosteric activators that modulate C2-domain calcium sensitivity or disrupt autoinhibitory conformations. As first-generation therapies approach advanced preclinical stages, the next wave of R&D is targeting isoform-specific modulation and combination strategies with SNARE complex regulators. The challenge remains the development of isoform-selective compounds that spare neuronal UNC13A to avoid CNS side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Neuro-focused Biotechs, Academic Consortia, Novo Nordisk (early research) | Epilepsy / Neurological Disorders, Type 2 Diabetes, Beta-cell Dysfunction | C2 Domain Calcium Binding Assay (Need high-purity lipid-binding domains) |
| ASO / siRNA | Gene Therapy Pioneers, Academic Gene Therapy Labs | Neurodevelopmental Diseases, Monogenic Diabetes | Knockdown Validation (Need high-efficiency delivery) |
| Targeted Protein Degrader | Emerging Startups | Neuro-oncology | Degradation Assays (Need Mutant vs WT Proteins) |
| Peptide Disruptors | Preclinical Biotech | Congenital Hyperinsulinism | MUN Domain/Syntaxin Interaction (Need stable MUN domain constructs) |
| Chemical Genomics | NIH/Academic Screening Centers | Metabolic Syndrome | High-throughput Vesicle Trafficking (Need validated siRNA controls) |
Molecular Differentiation & Assay Strategy
UNC13B, as a large (~150 kDa) multi-domain protein, presents unique challenges for drug development. Key differentiation factors include:
- Calcium Sensitivity: C2 domains bind phosphatidylserine (PS) and PIP2 in a calcium-dependent manner. Compounds must be distinguished as calcium sensitivity modulators vs. direct binding inhibitors.
- Isoform Selectivity: UNC13B (islet-enriched) vs. UNC13A (neuronal-enriched) differ in C1 and C2C domains. Lead compounds must show >100-fold selectivity window to avoid CNS side effects.
- Delivery: As an intracellular protein, traditional antibodies are ineffective. Focus is on cell-permeable small molecules or CPP-based delivery.
- Mechanism: Ideal modulators enhance vesicle priming rather than simply increasing fusion events (which could deplete vesicle pools). Assays must distinguish these kinetic modes.
Recommended Screening Assays:
- SPR/BLI binding assays for small molecule affinity and selectivity against UNC13B and UNC13A.
- Cell-based knockdown/degradation assays using HEK293 or neuronal/beta-cell lines.
- Protein-protein interaction (PPI) assays to verify compound interference with UNC13B-SNARE complex assembly.
TarMart Solution Advantages:
- High-purity, sequence-verified recombinant proteins (C2A-C2B tandem, MUN domain) for selectivity and calcium-binding assays.
- Custom mutant protein development for drug resistance studies.
- Lentivirus particles for rapid stable cell line construction.
Related Target Recommendations (Cross-Selling)
For comprehensive synaptic vesicle release and insulin secretion pathway analysis, consider the following targets:
- STX1A (Syntaxin-1A): Core SNARE complex protein, direct binding partner of UNC13B.
- VAMP2: Vesicle-associated membrane protein, key marker for presynaptic function.
- STXBP1 (Munc18-1): Essential cofactor for UNC13B-mediated priming, forms core ternary complex.
- RIMS1: Molecular scaffold at active zone, critical for vesicle tethering.
- UNC13A: Neuronal isoform for CNS off-target toxicity counter-screening.